Proper cell function requires proper protein folding. Misfolding of specific proteins, caused either by mutation or environmental stress, underlies many human diseases, including cancer and diabetes and Parkinson's, Huntington's, and Alzheimer's disease. Protein folding has been studied for decades in the test tube, initially spearheaded by the classical studies of Anfinsen and colleagues (1) . Whereas in vitro studies continue to provide invaluable contributions toward developing a complete understanding of the fundamental physical and chemical forces that govern folding, there has been a concomitant and growing appreciation that the cellular environment presents unique challenges-as well as unique support systems-for protein folding that cannot be captured easily in testtube folding experiments. To understand how to keep cells healthy and how to correct diseased cells, we must understanding how proteins fold and misfold in vivo and define the mechanism of action of the cellular protein quality-control machinery (Fig. 1) . Since 1990, the biennial FASEB Protein Folding in the Cell conference has been devoted to bridging the gap between our understanding of how proteins fold in the test tube and the consequences for the cell should they misfold.
The Protein Folding in the Cell conference occupies a unique niche among summer conferences because of its ongoing success at drawing together cell biologists, geneticists, biophysicists, biochemists, theorists, and computational biologists to tackle the complex problems of protein folding and misfolding and their implications for human disease. The extent to which this meeting has played a central role in the development of the field cannot be overstated. Historically, biophysical chemists/theoreticians and cell biologists/geneticists who study protein folding rarely crossed paths. However, the complexity of the protein folding "problem" and the paucity of methods available to study it in detail require a deep and multidisciplinary attack. Recent progress has shown the value of this approach in tackling some of the major outstanding questions in the field.
At the 2014 meeting, held July 20 -25 at the Vermont Academy in Saxton's River, VT, the nine sessions and one Keynote Address covered every aspect of the protein-folding problem and its consequences for proper cell function. The titles of the scientific sessions were: "Principles of Protein Folding," "Functions of Chaperone Machines," "Cellular Responses and Protein Biogenesis," "Protein Folding and Trafficking Networks," "Biology and Biophysics of Amyloids and Aggregation," "Evolution of Proteins and Protein Machines," "Protein Quality Control and Degradation," "Stress Responses, Molecular Chaperones, and Signaling," and "Protein Maturation and Folding Decisions." In addition to the didactic sessions, another dynamic aspect of the conference was its three-poster sessions that featured 93 submitted abstracts. The meeting was attended by nearly 150 scientists from academia, industry, and publishing houses and began with a Keynote Lecture from Lila Gierasch (University of Massachusetts, Amherst). In her lecture, Dr. Gierasch elegantly illustrated the synergy created by combining in vitro and in vivo studies of protein folding, focusing on her recent nuclear magnetic resonance and other biophysical studies (3, 4) to understand the allosteric regulation of the heat shock protein (Hsp)70 class of molecular chaperones and the impact of our improved understanding of how misfolded proteins are routed through protein quality-control networks in vivo (5) .
Many of the scientific presentations were buoyed by recent methodological and conceptual advances, often developed first to study protein folding in vitro and in silico, and now being applied in vivo. These advances include improvements to protein folding and evolution algorithms, the development of novel, single-molecule and in vivo-compatible instrumentation to examine folding, and the realization that manipulating cellular protein quality-control networks provides a new tool with which to correct diseases that arise from aberrant protein conformations. In addition, new methods uniquely suited to studying cellular aspects of protein folding have brought previously unanswerable questions within reach. For example, it is now possible to knock down each gene in the human genome, to map the positions of ribosomes on every mRNA message in the cell, and to obtain high-resolution protein structure information via electron microscopy with a new generation of detectors. In the following sections, we highlight select topics from the conference, reference recent work in these areas, and discuss how these fields will likely mature in the near future.
FUNDAMENTAL ASPECTS OF PROTEIN FOLDING
One exciting development is our growing appreciation of the diversity of protein-folding mechanisms and the high level of conformational dynamics in some native structures. Notably, significant changes in conformational ensembles can occur upon the binding of a protein to a ligand or partner protein. In the most extreme cases of intrinsically disordered proteins (IDPs), the bulk of folding occurs only on substrate binding. Although some residual structure persists in the unbound conformational ensemble of IDPs (6), recent work has challenged the idea that features present in this residual structure are crucial for the binding mechanism (7). More broadly, several talks and posters throughout the conference delved into the interplay between entropic and enthalpic contributions to protein folding and stability, including kinetic stability (8) and its ability to suppress aggregation (9) . Another common theme was the diverse ways that protein structures and folding mechanisms respond to amino acid mutations (10, 11) . Building upon this biophysical foundation, other presentations highlighted recent insights into the effects of macromolecular crowding (12) , molecular chaperones (13) , and other nanomachines on protein-folding mechanisms, protein stability, and the competition between productive protein folding and protein aggregation in vivo.
NANOMACHINES AND PROTEIN FOLDING
Efforts to understand the effects of the cellular environment on protein folding first started with the discovery of molecular chaperones. Whereas chaperones remained a major focus of the conference (see below), an emerging theme was the broad range of other differences between protein folding in the cell and in the test tube and the effects of chaperones on protein folding in vivo. For example, in the test tube, a protein has one of two possible fates: fold correctly or misfold/ aggregate. However, in vivo, another alternative exists: degradation. Cellular degradation machines tend to be large and complex, which has complicated our understanding of their mechanisms for substrate recognition and degradation. An excellent, recent example of the synergy between in vitro method development and in vivo mechanistic insights-a hallmark of this interdisciplinary conference-was the use of single-molecule optical trapping to reveal the connections between substrate unfolding and translocation into the ClpXP degradation machine (14) .
Likewise, in vitro, a protein may begin to fold by forming stabilizing interactions between any two portions of the polypeptide chain, whereas in vivo, the N terminus of a newly synthesized protein emerges, first, in the cytoplasm [or endoplasmic reticulum (ER) lumen or bacterial periplasm] and can begin to fold before more C-terminal portions of the polypeptide chain become available. This "vectorial" folding process can significantly alter protein-folding mechanisms when compared with the folding of a full-length protein on dilution out of a chemical denaturant (15) . However, the technical challenges of monitoring vectorial folding have limited the number of studies that examine this phenomenon (16 -18) . Several presentations delineated in unprecedented detail the roles of ribosome-and translocon-associated proteins in the folding and processing of newly synthesized proteins (19, 20) . Moreover, from the nascent chain perspective, we now know that cotranslational folding of a nascent, ribosome-bound protein can affect its translocation into the ER, even while still buried within the ribosome exit tunnel (21) . Given the rudimentary status of our understanding of the cellular strategies to improve the folding yield for large, complex proteins (22), we anticipate that many more regulatory mechanisms remain to be discovered.
CHAPERONE GYMNASTICS
The most basic definition of a molecular chaperone is a protein that prevents the aggregation of another protein or that facilitates the acquisition of protein structure, function, and/or localization. Prominent molecular chaperones-many of which are ATPasesinclude Hsp110, the Hsp104/Clp family, Hsp90, Hsp70, Hsp40, the oligomeric TCP-1 ring complex (TRiC) and GroEL/ES complexes, and the small Hsps. Through the development of new genetic screens, additional nonclassical chaperones are still being identified (23) . Talks and posters on each of these proteins and protein complexes were featured at the meeting. A major leap in our understanding of the functions of these chaperones emerged from structural work, which began in the ϳ1990s and has continued to reveal new insights. For example, TriC and GroEL/ES form cages that encapsulate unfolded or partially unfolded protein substrates. Recent work has led to a view of how ATP drives the dynamics of these machines (24) and how substrates engage the walls of the cage, an interaction that may directly facilitate protein folding (25, 26) . In turn, Hsp70s couple ATP binding and hydrolysis to the binding and release of relatively short peptide sequences. The allosteric changes that coordinate the actions of the ATP and substrate domains have been defined recently at unprecedented levels (4, 27) . The structural basis of the Hsp90 machine, which acts later than Hsp70 in protein-folding pathways, has been more difficult to dissect as a result of its complex, ATP-driven cycle, the presence of several protein-binding surfaces, and the existence of numerous cochaperones that regulate substrate association and Hsp90 function. However, the combination of genetic attacks, new biophysical methods, and additional model substrates has now placed the field at the cusp of defining the specific action of these diverse protein architects [see, for example, refs. (28, 29) ], an effort that will prove particularly relevant as the number of disease-causing substrates of chaperones rises. A discussion of these diseases-and how they might be treated-was also an ongoing and an active area of discussion at the conference.
PROTEIN SYNTHESIS FACTORIES AND CELLULAR DECISIONS
Proteins are synthesized by ribosomes, and for some time, it has been clear that nascent polypeptides emerging from the ribosome or soon after their release associate with molecular chaperones, including each of those listed above (30) . However, only now are we developing an understanding of how the ribosomeassociated chaperones select and compete for nascent polypeptides. As a result of cellular stresses, errors during transcription and translation, and inherited genetic mutations, many proteins misfold, which targets these substrates for degradation. As presented in several talks and posters, we now better understand how ribosome populations are distributed throughout the cytoplasm and associate with intracellular organellesmost notably, the ER (31) and mitochondria-and how protein-folding pathways can commence cotranslationally (32, 33) and after insertion into the ER (19) . A significant challenge in the future will be to "watch" the protein-folding reaction from start to finish, thus defining the interplay between the synthesis and folding machineries.
Another challenge is to reduce the levels of protein aggregates that can arise when the concentration of misfolded proteins rises in the cytoplasm. Indeed, the function of most chaperones is to prevent the formation of aggregates, yet the chaperone machinery may be overwhelmed while performing other functions as a result of cellular stress (31) . Even cellular and organismal aging can be viewed as a cellular stress, as aggregate formation becomes more robust. Well-known and toxic aggregates include those that arise from huntingtin (Huntington's disease), the amyloid peptide (Alzheimer's disease), and infectious prions, all of which can form regular, repeating structures (34) . Fortunately, some chaperones (e.g., the Hsp104/Clp family) are disaggregases, and in other cases, chaperone ensembles may function with one another to dissolve small aggregates (35) . Nevertheless, not all aggregates harm the cell. Instead, the preaggregate (or misfolded protein) can be toxic. Recent progress in our understanding of the underlying biophysics that govern the assembly of these structures and their effects on cellular functions was reported at the meeting.
Approximately one-third of all proteins in eukaryotes interacts with the ER membrane during or soon after synthesis, which results in the deposition of the nascent polypeptide within the ER lumen. High-resolution structures of the protein-translocation machinery continue to provide us with an unprecedented understanding of this event (36) and how the synthesis of new proteins is regulated. Within the ER, the proteinfolding pathway for this subset of proteins is completed, and the substrate may be secreted from the cell, reside in an intracellular compartment, or become a denizen of the plasma membrane. As may occur in the cytoplasm, some proteins misfold in the ER, which wreaks havoc on cellular function. Therefore, eukaryotic cells trigger an unfolded protein response (UPR), which tempers ER stress by up-regulating chaperone production, slowing protein synthesis, and increasing lipid synthesis and thus, ER volume (37) . Another way to temper ER stress is the ER-associated degradation (ERAD) pathway, during which misfolded proteins are ejected from the ER and destroyed by a multicatalytic, cytoplasmic protease, the proteasome (38) . Should the UPR and ERAD be unable to mitigate ER stress, a cell may self-destruct via the apoptotic pathway. Only recently has the ER stress-induced apoptotic pathway been defined (39) . Moreover, many of the molecular underpinnings of the "decision" to degrade ERAD substrates and to initiate the UPR are still unclear, but recent work-represented throughout the meetinghighlighted the nature of these decisions. A better definition of these events is critical, especially as numerous diseases are associated with defects in ER proteinquality control (40) .
TISSUE AND ORGANISMAL PROTEOSTASIS
A vital area of future research will be to define how cellular phenomena impact organism growth, development, and homeostasis. For many years, this proved challenging, but through the development of multicellular organism models that can be manipulated genetically, we are beginning to appreciate how the misfolding of disease-associated proteins, cellular stress, and aging affect protein homeostasis-or "proteostasis"-at the organismal level (41) . We are even beginning to appreciate how insults in a single cell type, such as a neuron, can initiate long-range effects in an animal (42) . These efforts are critical, as drug screens are typically performed with platforms that use protein isolates or cellular readouts, each of which has limitations. However, significantly better modulators of Hsp70 are now being identified (43) , as reported at the meeting, as well as Hsp90, which is an anticancer target (44). Engineered animal systems may then provide a superior route to report on the effects of drugs on proteostatic pathways and organismal health.
CONCLUSIONS AND PERSPECTIVES
Whereas the conference covered many exciting, recent discoveries, it is clear that there is still far more that we do not yet understand about how the cell efficiently produces and maintains its proteome. The complexity of the cellular environment and its position far from equilibrium continue to restrict the range of methods available to study protein folding in vivo, yet novel mass spectrometry and fluorescence approaches, among others, are poised to complement methods in genetics and cell biology to reveal mechanistic details in unprecedented detail. New developments will surely emerge in this dynamic and growing field.
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